Mylan N.V. (MYL) to Release Quarterly Earnings on Monday

Mylan N.V. (NASDAQ:MYL) will be issuing its quarterly earnings data before the market opens on Monday, November 6th. Analysts expect the company to announce earnings of $1.20 per share for the quarter. Mylan N.V. has set its FY17 guidance at $4.30-4.70 EPS.

Mylan N.V. (NASDAQ:MYL) last released its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter in the previous year, the business earned $1.16 EPS. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, analysts expect Mylan N.V. to post $4.63 EPS for the current fiscal year and $5.29 EPS for the next fiscal year.

Mylan N.V. (MYL) traded down 0.37% during mid-day trading on Monday, reaching $38.21. The company’s stock had a trading volume of 475,832 shares. The firm’s 50 day moving average price is $35.12 and its 200 day moving average price is $36.26. The stock has a market cap of $20.49 billion, a price-to-earnings ratio of 30.89 and a beta of 1.30. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87.

COPYRIGHT VIOLATION WARNING: This news story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at

Several equities analysts have recently commented on the company. Citigroup Inc. set a $42.00 price target on Mylan N.V. and gave the company a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. UBS AG reiterated a “buy” rating and issued a $46.00 price objective (down previously from $50.00) on shares of Mylan N.V. in a report on Thursday, August 10th. BidaskClub upgraded Mylan N.V. from a “strong sell” rating to a “sell” rating in a report on Thursday, September 7th. Finally, Instinet reiterated a “buy” rating and issued a $37.00 price objective on shares of Mylan N.V. in a report on Thursday, October 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $41.21.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Earnings History for Mylan N.V. (NASDAQ:MYL)

What are top analysts saying about Mylan N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Mylan N.V. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit